# Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

> **NCT02745080** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 853 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **BIOLOGICAL:** Secukinumab
- **BIOLOGICAL:** Adalimumab

## Key facts

- **NCT ID:** NCT02745080
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-03
- **Primary completion:** 2019-12-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 853 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02745080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02745080, "Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02745080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*